Antiplaque, Antigingivitis and Anti-inflammatory Effects of Myrrh Mouthwash

Gingivitis Clinical Trial

Official title:

A Clinical Study Comparing the Antiplaque, Antigingivitis and Anti-inflammatory Effects of Myrrh Mouthwash With Chlorhexidine Mouthwash in a 14-Day Experimental Gingivitis Model

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04723732
• Other study ID #: 058-15
• Status: Completed
• Phase: N/A
• Start date: August 15, 2017
• Est. completion date: December 15, 2018

Study information

• Verified date: January 2021
• Source: King Abdulaziz University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Myrrh-based mouthwash has the potential to be a suitable alternative to the gold standard chlorhexidine mouthwash for dental plaque and gingivitis reduction. To date, however, little research has been carried out to determine its true clinical significance on periodontal health. The purpose of this study is to evaluate and compare the efficacy of 1% myrrh mouthwash with commercially available 0.2% chlorhexidine mouthwash in terms of plaque and gingivitis reduction and inflammatory mediator (interleukin-1β) inhibition.

Description:

This will be a single-center, triple-blinded, randomized, three-arm parallel, controlled trial in periodontally healthy adult volunteers (no clinical attachment loss and bleeding on probing < 10%). We will include all eligible patients seeking dental treatment at the center after gaining a written informed consent. After the initial dental screening and a session of professional teeth cleaning procedures, participants will be instructed to refrain from regular oral hygiene practices for 2 weeks to develop experimental gingivitis. Participants will then be randomly allocated to one of the three treatment groups [1:1:1] using a simple randomization method (i.e. computer-generated random numbers). They will be instructed to continue refrain from regular oral hygiene practices and use 10 ml of the assigned mouthwash twice daily for 1 minute. Treatment effect will be evaluated by comparing the baseline (day 0) and post-intervention (day 14) values of all clinical parameters (modified gingival index, plaque index, proinflammatory interleukin-1β biomarker, and Gingival Bleeding Index).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: December 15, 2018
• Est. primary completion date: August 15, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• good periodontal health;

• dentition of =20 teeth and a minimum of 5 teeth per quadrant;

• the absence of any systemic illness;

• no history of oral prophylaxis in the past 6 months;

• no relevant medical history that might compromise normal oral hygiene practice.

Exclusion Criteria:

• pocket depth >3 mm

• severe misalignment of teeth;

• the presence of orthodontic appliances;

• intake of antibiotic and/or anti-inflammatory medications within the past 6 months;

• use of tobacco;

• inability of comply with the study's appointment schedule;

• pregnant or breast-feeding mothers.

Related Conditions & MeSH terms

• Dental Plaque
• Gingivitis

Intervention

Drug:
• Myrrh mouthwash
1% mouthwash solution of commiphora myrrha, made from Commiphora Myrrha resin extract.
• Chlorhexidine mouthwash
0.2% mouthwash solution of chlorhexidine gluconate.
• Normal saline
0.9% solution of sodium chloride, containing 9 g/L Sodium Chloride (154 mEq/L sodium and 154 mEq/L chloride)

Locations

Country	Name	City	State
Saudi Arabia	King Abdul Aziz University	Jeddah	Makkah

Sponsors (1)

Lead Sponsor	Collaborator
King Abdulaziz University

Country where clinical trial is conducted

Saudi Arabia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in inflammation on the proinflammatory interleukin (IL)-1ß biomarker at Day 14	IL-1ß is an important mediator of the inflammatory response. Elevated IL-1ß levels have been reported in a number of infectious disease conditions and in noninfectious inflammatory conditions. Human IL-1ß ELISA kit by BioVendor was utilized to determine the IL-1ß level. Preparation of reagents, execution of test protocol, and calculation of results were done adhering to the manufacturer's Product Data Sheet enclosed with the kit. The absorbance of each strip was read on a spectro-photometer at 450 nm wave length.	Baseline and Day 14
Secondary	Change from Baseline in gingivitis on the 4-point Modified Gingival Index (MGI) at Day 7 and 14	The MGI is a noninvasive visual assessment tool to assess the severity of gingivitis over time. It uses a rating score between 0 (normal gingiva) and 3 (severe inflammation with tendency to spontaneous bleeding). Change = (Day 14 Score - Baseline Score)	Baseline, Day 7, and Day 14
Secondary	Change from Baseline in plaque accumulation on O'leary Plaque Index (PI) at Day 7 and 14	The PI is a validated assessment tool based on recording of the presence of soft debris and mineralized deposits on all 4 surfaces of all teeth. It uses a rating score between 0 (no plaque) and 1 (plaque present at gingival margin). Change = (Day 14 Score - Baseline Score)	Baseline, Day 7, and Day 14
Secondary	Change from Baseline in gingival bleeding on the Gingival Bleeding Index (GBI) at Day 14	The GBI is a reliable indicator of gingival inflammation and periodontal stability. It uses gentle probing of the orifice of the gingival sulcus. The bleeding on probing (BOP) was assessed using a standardized periodontal probe with a 0.6 mm tip and 1 mm marking. A trained examiner measured BOP applying probing forces not exceeding 0.25 N (25 g). A positive finding was recorded if bleeding occured within 10 seconds.	Baseline and Day 14